Oncopeptides Q2 FY26 operating loss narrows to SEK 48.7 million; net sales rise 62% to SEK 31.1 million vs Q2 FY25

Reuters2026/08/27 06:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncopeptides posted Q2 net sales of SEK 31.1 million, up 62% year on year.
Operating loss narrowed to SEK 48.7 million; loss after tax improved to SEK 54.7 million.
EPS was SEK -0.14, improving from a larger loss a year earlier.
Cash and cash equivalents rose to SEK 157.6 million, following a March rights issue that added SEK 167 million net.
EMA Type II variation filing seeks to expand Pepaxti into third-line treatment; CHMP opinion expected between September and November 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncopeptides Q2 FY26 operating loss narrows to SEK 48.7 million; net sales rise 62% to SEK 31.1 million vs Q2 FY25

You may also like

Crypto prices